Skip Navigation

European Heart Journal 2008 29(4):429-431; doi:10.1093/eurheartj/ehm624
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Roffi, M.
Right arrow Articles by Mukherjee, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roffi, M.
Right arrow Articles by Mukherjee, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Platelet glycoprotein IIb/IIIa receptor inhibitors—end of an era?

Marco Roffi1,* and Debabrata Mukherjee2

1 Department of Cardiology, University Hospital, CH-1211 Geneva, Switzerland
2 Gill Heart Institute and Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY, USA

* Corresponding author. Tel: +41 22 37 27 208, Fax: +41 22 37 27 229, Email: marco.roffi@usz.ch

This editorial refers to ‘One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidrogel: results of the ISAR-REACT-2 randomized trial’ by G. Ndrepepa et al.,{dagger} on page 455

Footnotes

The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.

The first 10% of the full text of this article appears below.

The second Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT-2) study randomized 2022 high-risk patients with non-ST-segment elevation acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) to receive abciximab or placebo in addition to aspirin and clopidogrel 600 mg loading dose administered at least 2 h prior to the procedure. All patients received periprocedural unfractionated heparin. The incidence of the primary end-point of the study—the composite of death, myocardial infarction (MI), or urgent target vessel revascularization (TVR) at 30 days—was significantly reduced by 25% in the abciximab group.1 No difference was observed in terms of major or minor bleeding events between treatment assignments. In the present issue of the journal, Ndrepepa et al. have demonstrated . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial
Gjin Ndrepepa, Adnan Kastrati, Julinda Mehilli, Franz-Josef Neumann, Jurriën ten Berg, Olga Bruskina, Franz Dotzer, Melchior Seyfarth, Jürgen Pache, Josef Dirschinger, Peter B. Berger, and Albert Schömig
EHJ 2008 29: 455-461. [Abstract] [Full Text]